NEW YORK, August 5, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Oculus Innovative Sciences Inc. (NASDAQ: OCLS),
The Medicines Company (NASDAQ: MDCO), Supernus Pharmaceuticals Inc.
(NASDAQ: SUPN), Sophiris Bio Inc. (NASDAQ: SPHS), and Rigel
Pharmaceuticals Inc. (NASDAQ: RIGL). Free research report on Oculus
Innovative Sciences can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=OCLS On
Tuesday, August 04, 2015, the NASDAQ
Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial
Average lost 0.27%, to finish the day at 17,550.69, and the S&P
500 closed at 2,093.32, down 0.22%. The losses were broad based as
seven out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
Oculus Innovative Sciences Inc.'s stock plummeted 8.51%, to
close the day at $1.29. The stock
recorded a trading volume of 0.85 million shares, much below its
three months average volume of 1.34 million shares. Over the last
one month and since the start of this year, Oculus Innovative
Sciences Inc.'s shares have declined 18.35% and 9.79%,
respectively. However, the stock has rallied 78.67% in the previous
three months. The company's shares are trading 4.59% above their
200-day moving average. Additionally, Oculus Innovative Sciences
Inc. has a Relative Strength Index (RSI) of 40.32. Sign up and read
the free notes on OCLS at:
https://www.EquityResearchInstitute.com/reports?keyword=OCLS
On Tuesday, shares in The Medicines Co. recorded a trading
volume of 0.60 million shares, lower than their three months
average volume of 1.16 million shares. The stock ended the day
0.03% higher at $31.02. Although, The
Medicines Co.'s stock has lost 5.31% in the last one month, it has
advanced 17.99% in the previous three months and 12.11% on YTD
basis. The company is trading above its 50-day and 200-day moving
averages by 1.26% and 11.52%, respectively. Furthermore, shares of
The Medicines Co. have an RSI of 42.95. The complimentary notes on
MDCO can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=MDCO
Supernus Pharmaceuticals Inc.'s stock edged 0.76% higher, to
close Tuesday's session at $21.26.
The stock recorded a trading volume of 0.69 million shares, below
its three months average volume of 1.14 million shares. Over the
last one month and the previous three months, Supernus
Pharmaceuticals Inc.'s shares have surged 22.89% and 69.54%,
respectively. Additionally, the stock has rallied 156.14% since the
start of this year. The company is trading 22.54% and 80.05% above
its 50-day and 200-day moving averages, respectively. Furthermore,
Supernus Pharmaceuticals Inc.'s stock traded at a PE ratio of 29.12
and has an RSI of 68.31. Register for free on Equity Research
Institute and access the latest research on SUPN at:
https://www.EquityResearchInstitute.com/reports?keyword=SUPN
Sophiris Bio Inc.'s stock finished Tuesday's session 4.98% lower
at $0.80. A total of 0.09 million
shares were traded, which was much below its three months average
volume of 0.83 million shares. Over the last one month and the
previous three months, Sophiris Bio Inc.'s shares have gained 0.25%
and 13.76%, respectively. Additionally, the stock has surged 48.52%
since the beginning of 2015. The company's shares are trading below
their 50-day and 200-day moving averages by 12.90% and 27.32%,
respectively. Sophiris Bio Inc.'s stock has an RSI of 41.47. The
complete research on SPHS is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=SPHS
On Tuesday, shares in Rigel Pharmaceuticals Inc. ended the
session 2.93% higher at $3.16. The
stock reported a trading volume of 0.32 million shares, below its
three months average volume of 0.65 million shares. Although, Rigel
Pharmaceuticals Inc.'s shares have lost 21.00% in the previous
three months, it has advanced 2.27% in the last one month and
39.21% on YTD basis. The stock is trading 7.62% above its 200-day
moving average. Moreover, shares of Rigel Pharmaceuticals Inc. have
an RSI of 51.18. Free in-depth research on RIGL is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=RIGL
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com